Table 5.

Summary of results from Cost Utility Analysis (CUA)

Scenario	Incremental costs	Incremental effects	ICER (5th, 95th centile)
Overall (base case)†	£7090	0.139	£202 571
Rash subgroup
Base case‡	£7891	0.139	£56 770 (£29 438 –£89 550 )
Excluding erlotinib costs	£347	0.139	£2496 (£1120–£3895)
Including ENR 1st cycle drug costs§	£9578	0.139	£68 906 (£44 165–£93 276 )

†Erlotinib versus placebo (n=647).

‡ER versus placebo (n=456).

§ER (including ENR first cycle erlotinib costs) versus placebo.

ENR, Erlotinib non-rash; ICER, incremental cost-effectiveness ratio.